By using a high-throughput platform to test compounds, Mathews et al. found that ibrutinib was able to cooperate with other drugs including inhibitors of PI3K pathway (agents targeting the PI3K catalytic subunit, AKT, and the mTORC1 complex), BCL2 inhibitors, and cytotoxic chemotherapeutic drugs in killing ABC DLBCL cells (129). Here, AKT1 is linked to diffuse large B-cell lymphoma.